

Derek R Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4415144/publications.pdf>

Version: 2024-02-01

67
papers

2,104
citations

361413

20
h-index

243625

44
g-index

69
all docs

69
docs citations

69
times ranked

3824
citing authors

#	ARTICLE	IF	CITATIONS
1	An 82-year-old man with a right frontal lobe rim-enhancing lesion. <i>Brain Pathology</i> , 2022, 32, e13021.	4.1	1
2	Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults. <i>Journal of Neuro-Oncology</i> , 2022, 158, 139-165.	2.9	5
3	Cavernous Sinus Vascular Venous Malformation. <i>American Journal of Neuroradiology</i> , 2022, 43, 19-23.	2.4	3
4	Temporal Trends in Glioblastoma Survival. <i>Neurologist</i> , 2022, 27, 119-124.	0.7	7
5	Intracranial neuroendocrine tumour simulating meningioma for several years: an overview of diagnosis and treatment. <i>BJR case Reports</i> , 2022, 8, .	0.2	0
6	A 76-year-old male with multiple enhancing brain lesions. <i>Brain Pathology</i> , 2022, 32, e13063.	4.1	0
7	18F-fluorodeoxyglucose PET/Computed Tomography. <i>PET Clinics</i> , 2022, 17, 249-263.	3.0	2
8	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Progressive Glioblastoma in Adults: Update of the 2014 Guidelines. <i>Neurosurgery</i> , 2022, 90, e112-e115.	1.1	1
9	Manifestations of radiation toxicity in the head, neck, and spine: An image-based review. <i>Neuroradiology Journal</i> , 2022, 35, 427-436.	1.2	1
10	Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	7
11	Diffuse Calvarial Hyperostosis and Spontaneous Intracranial Hypotension: A Case-Control Study. <i>American Journal of Neuroradiology</i> , 2022, 43, 978-983.	2.4	5
12	Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease. <i>Neuro-Oncology Practice</i> , 2021, 8, 11-17.	1.6	0
13	Diffuse Calvarial Hyperostosis in Patients with Spontaneous Intracranial Hypotension. <i>World Neurosurgery</i> , 2021, 146, e848-e853.	1.3	9
14	Growth hormone deficiency in a child with <sc>branchio-oto-renal</sc> spectrum disorder: Clinical evidence of <sc>EYA1</sc> in pituitary development and a recommendation for pituitary function surveillance. <i>American Journal of Medical Genetics, Part A</i> , 2021, 185, 261-266.	1.2	1
15	Intracranial long-term complications of radiation therapy: an image-based review. <i>Neuroradiology</i> , 2021, 63, 471-482.	2.2	18
16	Efficacy of 177Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 236-240.	2.4	5
17	Diffuse Gliomas of the Brainstem and Cerebellum in Adults Show Molecular Heterogeneity. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1082-1090.	3.7	12
18	Comparison of Radiologists and Other Specialists in the Performance of Lumbar Puncture Procedures Over Time. <i>American Journal of Neuroradiology</i> , 2021, 42, 1174-1181.	2.4	8

#	ARTICLE	IF	CITATIONS
19	Cerebral malaria with extensive subcortical microhemorrhages. Oxford Medical Case Reports, 2021, 2021, omab028.	0.4	0
20	Neuro-Oncology Practice Clinical Debate: FDG PET to differentiate glioblastoma recurrence from treatment-related changes. Neuro-Oncology Practice, 2021, 8, 518-525.	1.6	3
21	Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation. Journal of Neuropathology and Experimental Neurology, 2021, 80, 821-829.	1.7	13
22	Frequency and Characteristics of Nodal and Deltoid FDG and ¹¹ C-Choline Uptake on PET Performed After COVID-19 Vaccination. American Journal of Roentgenology, 2021, 217, 1206-1216.	2.2	30
23	Neuro-Oncology Practice Clinical Debate: stereotactic radiosurgery or fractionated stereotactic radiotherapy following surgical resection for brain metastasis. Neuro-Oncology Practice, 2020, 7, 263-267.	1.6	4
24	Enlarging Perivascular Spaces Following Radiation Therapy in the Brain: A Report of 2 Cases and Literature Review. World Neurosurgery, 2020, 138, 436-439.	1.3	4
25	Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity. Cancer Chemotherapy and Pharmacology, 2020, 86, 375-382.	2.3	1
26	CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings. NeuroImage: Clinical, 2020, 28, 102481.	2.7	5
27	A focus on psychological needs of brain tumor patients and leveraging epidemiology. Neuro-Oncology Practice, 2020, 7, 463-464.	1.6	1
28	“Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro-Oncology, 2020, 22, 936-943.	1.2	77
29	PET Imaging of Tumor Perfusion: A Potential Cancer Biomarker?. Seminars in Nuclear Medicine, 2020, 50, 549-561.	4.6	9
30	Review of WHO 2016 Changes to Classification of Gliomas; Incorporation of Molecular Markers. , 2020, , 127-138.		2
31	Neuro-Oncology Practice Clinical Debate: long-term antiepileptic drug prophylaxis in patients with glioma. Neuro-Oncology Practice, 2020, 7, 583-588.	1.6	5
32	Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology, 2019, 61, 1327-1332.	2.2	48
33	Pitfalls of a Mixed Metabolic Response at PET/CT. Radiographics, 2019, 39, 1461-1475.	3.3	12
34	PET Imaging of Hepatocellular Carcinoma. Current Radiology Reports, 2019, 7, 1.	1.4	0
35	Preliminary exploration of a computerized cognitive battery and comparison with traditional testing in patients with high-grade glioma. Neuro-Oncology Practice, 2019, 6, 71-77.	1.6	10
36	There is an exception to every rule—T2-FLAIR mismatch sign in gliomas. Neuroradiology, 2019, 61, 225-227.	2.2	52

#	ARTICLE	IF	CITATIONS
37	Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma. <i>Neuro-Oncology Practice</i> , 2019, 6, 17-21.	1.6	7
38	Glioma response assessment: Classic pitfalls, novel confounders, and emerging imaging tools. <i>British Journal of Radiology</i> , 2019, 92, 20180730.	2.2	10
39	Dual-Energy CT Differentiates Contrast Staining From Hemorrhagic Conversion of Ischemic Stroke. <i>Neurohospitalist, The</i> , 2018, 8, 42-43.	0.8	1
40	Overall survival in patients with glioblastoma before and after bevacizumab approval. <i>Current Medical Research and Opinion</i> , 2018, 34, 813-820.	1.9	31
41	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. <i>Journal of Neuro-Oncology</i> , 2018, 136, 373-378.	2.9	9
42	Case-based review: ependymomas in adults. <i>Neuro-Oncology Practice</i> , 2018, 5, 142-153.	1.6	8
43	Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. <i>American Journal of Neuroradiology</i> , 2017, 38, 678-684.	2.4	63
44	Revisiting Adjuvant Radiotherapy After Gross Total Resection of World Health Organization Grade II Meningioma. <i>World Neurosurgery</i> , 2017, 103, 655-663.	1.3	55
45	Case-based review: primary central nervous system lymphoma. <i>Neuro-Oncology Practice</i> , 2017, 4, 46-59.	1.6	3
46	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	2.2	7
47	2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. <i>Radiographics</i> , 2017, 37, 2164-2180.	3.3	105
48	Case-Based Review: meningioma. <i>Neuro-Oncology Practice</i> , 2016, 3, 120-134.	1.6	6
49	Socioeconomic status and glioblastoma risk: a population-based analysis. <i>Cancer Causes and Control</i> , 2015, 26, 179-185.	1.8	46
50	Case-Based Review: newly diagnosed glioblastoma. <i>Neuro-Oncology Practice</i> , 2015, 2, 106-121.	1.6	13
51	ED-25 * SOCIOECONOMIC STATUS MODIFIES THE IMPACT OF RACE/ETHNICITY ON GLIOBLASTOMA PROGNOSIS. <i>Neuro-Oncology</i> , 2014, 16, v71-v71.	1.2	0
52	Medical Management of High-Grade Astrocytoma: Current and Emerging Therapies. <i>Seminars in Oncology</i> , 2014, 41, 511-522.	2.2	21
53	Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis. <i>Cancer</i> , 2013, 119, 3489-3495.	4.1	95
54	Mortality and Discharge to Home After Closed Brain Biopsy: Analysis of 3523 Cases from the State of California, 2003-2009. <i>World Neurosurgery</i> , 2013, 79, 110-115.	1.3	16

#	ARTICLE	IF	CITATIONS
55	Incorporation of Prognostic and Predictive Factors Into Glioma Clinical Trials. <i>Current Oncology Reports</i> , 2013, 15, 56-63.	4.0	32
56	Relationship between cognitive function and prognosis in glioblastoma. <i>CNS Oncology</i> , 2013, 2, 195-201.	3.0	24
57	Rapid Symptomatic and Radiographic Evolution After Presumed Spontaneous Infarction of a Meningioma. <i>Neurologist</i> , 2012, 18, 409-412.	0.7	7
58	Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 808-816.	1.2	96
59	Recent Medical Management of Glioblastoma. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 26-40.	1.6	20
60	Biologic therapy for malignant glioma. , 2012, , 102-113.		0
61	Conditional probability of long-term survival in glioblastoma. <i>Cancer</i> , 2012, 118, 5608-5613.	4.1	79
62	Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. <i>Journal of Neuro-Oncology</i> , 2012, 108, 187-193.	2.9	103
63	Glioblastoma survival in the United States before and during the temozolomide era. <i>Journal of Neuro-Oncology</i> , 2012, 107, 359-364.	2.9	632
64	Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. <i>Neuro-Oncology</i> , 2011, 13, 530-535.	1.2	74
65	Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. <i>Cancer Genetics</i> , 2011, 204, 13-18.	0.4	77
66	Associations of High-Grade Glioma With Glioma Risk Alleles and Histories of Allergy and Smoking. <i>American Journal of Epidemiology</i> , 2011, 174, 574-581.	3.4	52
67	Risk factors for meningioma in postmenopausal women: results from the Iowa Women's Health Study. <i>Neuro-Oncology</i> , 2011, 13, 1011-1019.	1.2	50